Pharmacist Medication Insights: Darzalex Faspro for Multiple Myeloma
Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) was approved in July in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.
In July, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.
This was the sixth indication for daratumumab and hyaluronidase-fihj and followed Janssen’s FDA submission in November 2020.
Multiple myeloma is an incurable blood cancer that impacts plasma cells. When damaged, these cells spread rapidly and replace normal cells with tumors in the blood marrow. An estimated 34,000 people will be diagnosed with multiple myeloma in 2021 and close to 12,500 will die from the disease in the United States.
